Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
NCT03482479
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Boston, Massachusetts, United States
View Trial DetailsNCT Number: NCT00315406
Polyarteritis nodosa (PAN) is a rare immune system disorder that causes swelling and damage to small- and medium-sized blood vessels in the body. In order to properly treat this disease, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of disease in people with PAN.
Looking for future studies?
Notify MeAll sexes
Observational
St. Joseph's Healthcare, Hamilton, Ontario, Canada
PAN, also known as systemic necrotic vasculitis, was the first recognized form of primary systemic vasculitis. PAN causes the inflammation of small- to medium-sized blood vessels, especially those supplying the nerves, skin, kidneys, gastrointestinal tract, heart, eye, and genitals. Unlike another form of vasculitis called microscopic polyangiitis, PAN does not usually cause glomerulonephritis, a type of kidney disease, or vasculitis in the very smallest blood vessels (arterioles, capillaries, and venules). There are no radiographic or serologic tests that can reliably measure disease activity in PAN. Currently, clinicians must rely on patients' symptoms, signs, laboratory tests, and imaging to guide treatment decisions, but such data are rarely consistently reliable in determining PAN disease activity. This study will use new scientific methods to discover new biomarkers that can be used to monitor disease activity in PAN patients. These biomarkers may be used to help direct clinical care for PAN patients and assist in future drug development.
Study visits will occur monthly for the first year, then every 3 months thereafter for the remainder of the study. Blood and urine collection will occur at every visit. A physical exam and medical and medication history will occur every 3 months; also, participants will be asked to complete several questionnaires to assess disease activity, health status, and tobacco, alcohol, and drug use. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
MAJOR CRITERIA
MINOR CRITERIA
Exclusion criteria
Time frame: Study completion
Time frame: Study completion.
University of Pennsylvania
Other
Longitudinal Protocol of Polyarteritis Nodosa
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03482479
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Boston, Massachusetts, United States
View Trial DetailsNCT02190942
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Tampa, Florida, United States
View Trial DetailsNCT03410290
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Tampa, Florida, United States
View Trial DetailsNCT02190916
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Tampa, Florida, United States
View Trial Details